Abstract：
Parkinson\'s Disease (PD) remains a significant focus of extensive research aimed at developing effective therapeutic strategies. Current treatments primarily target symptom management, with limited success in altering the course of the disease. This shortfall underscores the urgent need for novel therapeutic approaches that can modify the progression of PD.This review concentrates on emerging therapeutic targets poised to address the underlying mechanisms of PD. Highlighted novel and emerging targets include Protein Abelson, Rabphilin-3 A, Colony Stimulating Factor 1-Receptor, and Apelin, each showing promising potential in preclinical and clinical settings for their ability to modulate disease progression. By examining recent advancements and outcomes from trials focusing on these targets, the review aims to elucidate their efficacy and potential as disease-modifying therapies.Furthermore, the review explores the concept of multi-target approaches, emphasizing their relevance in tackling the complex pathology of PD. By providing comprehensive insights into these novel targets and their therapeutic implications, this review aims to guide future research directions and clinical developments toward more effective treatments for PD and related neurodegenerative disorders.
摘要：
帕金森病（PD）仍然是广泛研究的重点，旨在开发有效的治疗策略。目前的治疗主要针对症状管理，在改变疾病进程方面的成功有限。这种不足强调了对可以改变PD进展的新型治疗方法的迫切需要。这篇综述集中于新兴的治疗靶标，以解决PD的潜在机制。突出的新的和新兴的目标包括蛋白质Abelson，Rabphilin-3A,集落刺激因子1-受体,和Apelin,它们在临床前和临床环境中都显示出有希望的潜力，因为它们具有调节疾病进展的能力。通过检查最近的进展和结果从试验集中在这些目标，本综述旨在阐明其作为疾病改善疗法的疗效和潜力.此外，这篇综述探讨了多目标方法的概念，强调它们在解决PD复杂病理方面的相关性。通过提供对这些新靶标及其治疗意义的全面见解，这篇综述旨在指导未来的研究方向和临床发展，以更有效地治疗PD和相关的神经退行性疾病。
